GSK-3 inhibitors sensitize not only TRAIL-induced, but also CH-11-induced apoptosis, making itself a potential candidate of cancer treatment in addition to its previously reported role in anti-inflammation [30]. This evidence concerns the gene TNFSF10 and cancer.